Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Assets (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Assets readings, the most recent being $20.9 million for Q4 2017.

  • On a quarterly basis, Assets rose 1646.82% to $20.9 million in Q4 2017 year-over-year; TTM through Dec 2017 was $20.9 million, a 1646.82% increase, with the full-year FY2017 number at $20.9 million, up 1646.82% from a year prior.
  • Assets hit $20.9 million in Q4 2017 for Eledon Pharmaceuticals, down from $23.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $107.7 million in Q4 2014 to a low of $1.2 million in Q4 2016.
  • Median Assets over the past 5 years was $46.9 million (2016), compared with a mean of $54.4 million.
  • Biggest five-year swings in Assets: tumbled 98.24% in 2016 and later skyrocketed 1646.82% in 2017.
  • Eledon Pharmaceuticals' Assets stood at $32.3 million in 2013, then surged by 233.71% to $107.7 million in 2014, then tumbled by 36.91% to $68.0 million in 2015, then tumbled by 98.24% to $1.2 million in 2016, then skyrocketed by 1646.82% to $20.9 million in 2017.
  • The last three reported values for Assets were $20.9 million (Q4 2017), $23.0 million (Q3 2017), and $26.8 million (Q2 2017) per Business Quant data.